These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22763953)

  • 1. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
    Lo Re V; Haynes K; Ming EE; Wood Ives J; Horne LN; Fortier K; Carbonari DM; Hennessy S; Cardillo S; Reese PP; Reddy KR; Margolis D; Apter A; Kimmel SE; Roy J; Freeman CP; Razzaghi H; Holick CN; Esposito DB; Van Staa TP; Bhullar H; Strom BL
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1202-15. PubMed ID: 22763953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
    Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
    Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.
    Hirshberg B; Parker A; Edelberg H; Donovan M; Iqbal N
    Diabetes Metab Res Rev; 2014 Oct; 30(7):556-69. PubMed ID: 24376173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
    Scirica BM; Braunwald E; Raz I; Cavender MA; Morrow DA; Jarolim P; Udell JA; Mosenzon O; Im K; Umez-Eronini AA; Pollack PS; Hirshberg B; Frederich R; Lewis BS; McGuire DK; Davidson J; Steg PG; Bhatt DL;
    Circulation; 2014 Oct; 130(18):1579-88. PubMed ID: 25189213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Mannucci E
    Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saxagliptin, alone or in combination. No fewer complications; more cases of heart failure?
    Prescrire Int; 2014 Sep; 23(152):207. PubMed ID: 25325118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.
    Fireman B; Toh S; Butler MG; Go AS; Joffe HV; Graham DJ; Nelson JC; Daniel GW; Selby JV
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():282-90. PubMed ID: 22262618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 10. Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?
    Cebrián-Cuenca AM; Orozco-Beltrán D; Navarro-Pérez J; Franch-Nadal J; Núñez-Villota J; Consuegra-Sánchez L
    Int J Cardiol; 2016 Oct; 220():573-4. PubMed ID: 27390991
    [No Abstract]   [Full Text] [Related]  

  • 11. Saxagliptin overview: special focus on safety and adverse effects.
    Ali S; Fonseca V
    Expert Opin Drug Saf; 2013 Jan; 12(1):103-9. PubMed ID: 23137182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes.
    Lo Re V; Carbonari DM; Saine ME; Newcomb CW; Roy JA; Liu Q; Wu Q; Cardillo S; Haynes K; Kimmel SE; Reese PP; Margolis DJ; Apter AJ; Reddy KR; Hennessy S; Bhullar H; Gallagher AM; Esposito DB; Strom BL
    BMJ Open Diabetes Res Care; 2017; 5(1):e000400. PubMed ID: 28878934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
    Jialal I; Dhindsa S
    Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
    Shubrook JH; Colucci RA; Schwartz FL
    Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
    Cook W; Bryzinski B; Slater J; Frederich R; Allen E
    Postgrad Med; 2013 May; 125(3):145-54. PubMed ID: 23748515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):383-94. PubMed ID: 22313172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
    Hardy G
    Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
    [No Abstract]   [Full Text] [Related]  

  • 19. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
    Scirica BM; Bhatt DL; Braunwald E; Steg PG; Davidson J; Hirshberg B; Ohman P; Price DL; Chen R; Udell J; Raz I
    Am Heart J; 2011 Nov; 162(5):818-825.e6. PubMed ID: 22093196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saxagliptin-induced recurrent acute pancreatitis.
    Lee CF; Sun MS; Tai YK
    Intern Med; 2014; 53(12):1351-4. PubMed ID: 24930656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.